Kcentra Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Kcentra market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth observed in the historical period can be attributed to factors such as the rising prevalence of bleeding disorders, increasing awareness of bleeding complications, regulatory approvals for prothrombin complex concentrate (PCC) products, a higher incidence of trauma and surgeries, and the growing use of anticoagulant therapies.

The anticipated growth in the forecast period is driven by factors such as the expanding geriatric population, an increasing demand for anticoagulant reversal agents, greater access to healthcare in emerging economies, a heightened focus on patient safety during surgeries, and the expansion of product indications by regulatory authorities. Key trends for the forecast period include the growth of personalized medicine, the adoption of point-of-care testing, advancements in plasma-derived products, the integration of artificial intelligence in coagulation management, and a growing preference for single-dose therapies.

The increasing prevalence of bleeding disorders is expected to drive the growth of the kcentra market. Bleeding disorders, such as hemophilia, von Willebrand disease (VWD), and acquired coagulopathies, are conditions that hinder the blood's ability to clot, resulting in prolonged or excessive bleeding. The rising incidence of these disorders is linked to genetic factors, improved diagnostic capabilities, and greater awareness, which have led to better identification of cases globally. Kcentra, a prothrombin complex concentrate, is used to treat bleeding disorders, especially in patients with vitamin K antagonists or warfarin-related bleeding. For example, the World Federation of Hemophilia estimated in October 2023 that hemophilia A affects 17.1 per 100,000 males, while hemophilia B affects 3.8 per 100,000, with severe cases being rarer. These statistics highlight the significant number of patients globally, which is contributing to the growth of the kcentra market.

Rising healthcare expenditure is expected to fuel the growth of the kcentra market. Healthcare expenditure refers to total spending on health services, including medical infrastructure, advanced treatments, emergency care, and surgeries. This increase in spending is driven by factors such as an aging population, chronic diseases, rising service costs, increased demand, technological advancements, higher drug prices, the impact of COVID-19, medical inflation, and income inequality. A significant portion of healthcare expenditure for Kcentra is directed towards treating urgent bleeding reversals caused by anticoagulant use, with substantial costs associated with its use in critical care and hospital settings. For example, the UK’s Office for National Statistics reported in May 2024 that healthcare spending increased by 5.6% from 2022 to 2023, compared to a 0.9% growth rate in 2022. Long-term health and social care expenditures also rose by 2.8% in real terms in 2022. Thus, rising healthcare expenditure is driving the growth of the kcentra market.

A key trend in the kcentra market is the approval of new therapies, such as Balfaxar (human prothrombin complex concentrate), which is driving advancements in the industry. Balfaxar is designed for the urgent reversal of acquired coagulation factor deficiencies caused by warfarin therapy in adult patients who require emergency surgery or invasive procedures. For example, in July 2023, Octapharma USA announced that the U.S. Food and Drug Administration (FDA) had approved Balfaxar for the emergency reversal of coagulation factor deficiencies in adult patients undergoing urgent surgeries. Balfaxar works by restoring blood clotting through the replenishment of deficient clotting factors caused by warfarin therapy. This approval is a significant step forward in the development of treatments for urgent anticoagulant-related bleeding, driving competitive advancements in the kcentra market.

The key company operating in the kcentra market is CSL Behring.

North America was the largest region in the kcentra market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in kcentra report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the kcentra market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Kcentra is a medication designed for the urgent reversal of vitamin K antagonists, such as warfarin, in patients experiencing major bleeding or requiring emergency surgery. It is a prothrombin complex concentrate that provides rapid correction of clotting factors, aiding in the restoration of normal blood coagulation. Kcentra is typically administered intravenously in healthcare settings and is known for its ability to quickly reverse the effects of anticoagulation, thereby reducing the risk of bleeding complications.

The primary indications for kcentra include the urgent reversal of warfarin therapy, treatment of acquired coagulation factor deficiencies, and management of major bleeding events. Urgent reversal of warfarin therapy involves the rapid restoration of normal clotting function in patients at risk of bleeding, often using vitamin K, fresh frozen plasma, or coagulation factor concentrates. The formulations of Kcentra include injectable forms and lyophilized powders for reconstitution. The patient demographics for Kcentra include pediatric, adult, and geriatric patients. It is distributed through direct sales, wholesalers, distributors, retail pharmacies, and online pharmacies, and is used by various end users such as hospitals, outpatient surgical centers, emergency departments, and specialty clinics.

The kcentra market research report is one of a series of new reports that provides kcentra market statistics, including kcentra industry global market size, regional shares, competitors with a kcentra market share, detailed kcentra market segments, market trends and opportunities, and any further data you may need to thrive in the kcentra industry. This kcentra market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The kcentra market consists of sales of profilnine, bebulin, and beriplex. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.